American CryoStem Corporation (CRYO)
American CryoStem Corporation; (CRYO or ACS) a biotechnology pioneer founded in 2008, is a strategic developer, marketer, and global licensor of patented adipose tissue-based cellular technologies, and cellular applications for the Regenerative and Personalized Medicine industries
Our primary services include processing and cryo-banking of pure adipose tissue for aesthetic and reconstructive use as a biocompatible filler and storage of Adipose Derived Stem Cell (ADSCs). ADSCs, namely Mesenchymal stem cells, are further cultured, expanded and stored to create best-in-class autologous personalized cellular therapies.
The Company is currently marketing its biocompatible filler product lines (CELLECT® and ATGRAFT ®), to our 150+ physician network and international licensees, and plans to expand marketing outreach to orthopedic surgeons and orthopedists with ATCELL® for orthopedic applications.
The Company is seeking convertible debt financing while the Company completes its transition from an early market FDA registered Tissue Bank to a cGMP Biologics Manufacturer.
The Company's near term objective is to 1) File an Investigational New Drug (IND) application; 2) Begin marketing and manufacturing autologous Mesenchymal stem cell therapies for orthopedic purposes only; 3) Submit two FDA 510(k) medical device filings; 4) Identify and pursue additional international partnering and licensing opportunities that will fully capitalize on the strengths of the Company’s 36 patents and turnkey Centralized Cellular Processing Platform.
Company Highlights: 2008-2018
American CryoStem Executive Summary
ACS Regenerative Medicine Platform
Regenerative & Personalized Medicine holds the promise of regenerating damaged tissues and organs in the body by stimulating the body’s own repair mechanisms to heal previously irreparable tissues and organs. The industry currently has three major categories where our platform and stem cell products participate;
We use our patented intellectual property to develop safe and effective cellular medicine products and applications for indications that represent a large unmet need globally. Our therapeutic pipeline of products and applications is based on technologies developed both in-house and obtained through licensing and collaboration arrangements with biotechnology companies.
We intend to utilize our comprehensive cellular platform to support cellular products related to gender, age, nationality, orthopedic applications and disease with partners that can efficiently develop treatments without having to rediscover and recreate the underlying technology for each new product.
An early adopter of utilizing adipose tissue as a stem cell source we have designed every process and product to standardize, validate and commercialize our platform.
Patented, modular, platform technology allows complete control of the stem cell processing and manufacturing chain for optimal standardized cellular characteristics.
Allowing a patient to improve their quality of life by easily preparing for their current or future regenerative medicine needs by utilizing our cellular platform with multiple products, (bio-insurance) allowing for usage at every stage of life.
American CryoStem (CRYO) is a leading developer, manufacturer, and marketer of life-enhancing, adipose tissue (fat) based stem cell technologies. The company offers a proprietary tissue collection, processing and cryo-storage platform for (current or future) regenerative medicine applications using adult stem cells to address the impact of aging, injury and other disorders.
Management Team http://www.americancryostem.com/our-leadership/
Current Projects http://www.americancryostem.com/investors/
NEWS Releases http://www.americancryostem.com/news/
Applications http://www.equitybuyers.net/wp-content/ uploads/2019/06/American_ CryoStem_ExecSummary.pdf
You must be logged in to post a comment.
2015 Powered By Iastra Broadcasting All Rights Reserved